加拿大券商巨头Canaccord Genuity因系统性反洗钱缺陷遭重创，美国FinCEN开出8000万美元天价罚单

Core Viewpoint - The article highlights the unprecedented $80 million civil penalty imposed on Canaccord Genuity LLC by FinCEN for serious violations of the Bank Secrecy Act, marking a significant shift in regulatory attitudes towards compliance failures in the financial services industry [1]. Penalty Structure - The $80 million fine is a result of a comprehensive settlement involving parallel investigations by the SEC and FINRA, with $5 million of the payment deferred based on the company's future compliance efforts. The total includes $20 million each to the SEC and FINRA, leaving an immediate cash payment of $35 million to the U.S. Treasury [3]. Root Causes of Violations - Canaccord's compliance failures stem from a significant gap between its aggressive business model and a virtually non-existent compliance framework. From 2018 to 2024, the company was a leading market maker in the OTC market, with nearly $70 billion in trading volume, particularly in low-priced and micro-cap stocks, which are prone to manipulation and fraud [5]. Systemic Deficiencies - The company's suspicious transaction monitoring was ineffective, with absurd thresholds that only captured extreme price movements while ignoring cross-day manipulation patterns. Manual filtering conditions for suspicious activity reports were severely distorted, leading to the exclusion of most suspicious activities. Additionally, compliance personnel were found to have fabricated nearly 400 documents to cover up their negligence [6]. Human Resource Issues - During peak business periods, only four employees were responsible for reviewing over 100 reports, with some reports left unaddressed for years. Many of these employees lacked anti-money laundering expertise, and the new compliance supervisor received only two days of training before assuming the role [7]. Client Due Diligence Failures - The company's client risk assessment methods were fundamentally flawed, categorizing clients based on account type rather than actual risk. This led to inadequate scrutiny of high-risk clients, even when their assets surged dramatically. The company failed to identify and manage clients holding bearer shares, which are recognized as high-risk [7]. Risk Exposure through Agency Accounts - Canaccord opened an agency account for a Bahamian bank without proper due diligence, neglecting to assess the nature of its business or country risk. Despite receiving inquiries about the account's suspicious activities from other financial institutions, no additional measures were taken [8]. Omitted Suspicious Activities - Regulatory reviews revealed that Canaccord failed to report at least 160 suspicious activity reports (SARs), with underlying suspicious transactions estimated in the thousands. Notable cases included failing to identify a stock price surge of over 100 times for Oncology Pharma and continuing to provide market-making services to Blue Eagle Lithium despite internal warnings [8]. Willful Negligence - The company's issues were not due to ignorance but rather a typical "regulatory arbitrage" mentality. FINRA had previously identified deficiencies in Canaccord's anti-money laundering monitoring as early as 2013, issuing multiple warnings over the years. Despite written commitments to rectify issues, the company delayed action, ultimately leading to severe penalties [10].